Antibacterial Drugs Market Size, Share & Industry Analysis, By Class (Lactams, Tetracycline, Quinolones, Macrolides, Sulphonamide, Others), By Route of Administration (Oral , Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Regional Forecast, 2024-2032

Antibacterial drugs are the compounds that are used against the bacteria which work by either inhibiting their growth of by killing them. Many classes of antibacterial drugs have been developed and are available according to their chemical nature, range of activity, and method of action. An increase in the incidences of infectious diseases resulting in the rise in the demand for antibacterial drugs is driving the market growth. Factors such as a rise in incidences of infectious diseases, growing healthcare spending, modernization of the healthacre infrastructure, and improving diagnosis rate are the major factor driving the growth of the market. According to the World Health Organization (WHO), more than 30 new infections have been estimated to have emerged in the last two decades, which threaten the health of millions of individuals.

Moreover, an increase in the frequencies of zoonotic diseases is also propelling the growth of the market. According to the Centers for Disease Control (CDC) in 2017, estimated that 3/4th of new or emergent infectious diseases in society come from animals. In addition, the growth of the market is also expected to be boosted by the multidrug-resistant bacteria known as superbugs. The overall growth of the market is rising due to factors such as significant investments in R&D activities, a rise in the incidences of infectious diseases, and zoonotic disease outbreaks.

However, stringent regulatory guidelines, resistance to the antibacterial drugs developed by the bacteria,  and high cost of drug approval are projected to obstruct the market growth.

Market Segmentation:

The global antibacterial drugs market can be segmented on the basis of class, route of administration, distribution channel, and region. Based on the class, the market can be segmented into B – lactams, tetracycline, quinolones, macrolides, sulfonamide, and others. Based on the route of administration, the market can be segmented into oral and parenteral. Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies

Geographically, the antibacterial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:

The major companies in the global antibacterial drugs report include Shionogi & Co., Ltd., Bayer AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Novartis AG, Allergan, and other prominent players.

Key Insights:

• New Antibacterial Drug Launch


• Disease Outbreaks in Key Countries


• Infectious Diseases Incidences for Key Countries


• Recent Antibacterial Drugs Research & Development Activities


• Key Industry Developments - Mergers, Acquisitions, and Partnerships

Regional Analysis:

Geographically, the global antibacterial drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically, North America is expected to account for the significant market share of the market, and it is also anticipated to retain its superiority throughout the forecast period. The region will prove to be a profitable market for antibacterial drug manufacturers due to enormous R&D expenditure and developing treatment solutions for superbugs. Europe's market is anticipated to holds the second-largest share in the market. However, Asia-Pacific possesses the high potential for growth of the market due to the rise in the geriatric population, an increase in the incidences of infectious & zoonotic diseases, growing R&D activities in this region as well as growing demand for improved antibacterial drugs at an affordable cost in the region. Latin America and the Middle East & Africa are increasing steadily in the market.

Segmentation

Antibacterial Drug Market Industry Developments

• In October 2019, GlaxoSmithKline plc announced the phase III clinical programme investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection and urogenital gonorrhea.


• In November 2019, Allergan plc announced the approval of Qualified Infectious Disease Product and Fast Track Designation by U.S. Food and Drug Administration (FDA) for ATM-AVI (aztreonam and avibactam), for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP).


• In November 2019, – Shionogi & Co., Ltd. announced the approval of FETROJA (cefiderocol) by the U.S. Food and Drug Administration (FDA) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.